Biologic drugs transformed the treatment of cancer, autoimmune disease, and diabetes, but their cost has kept many patients and health systems from benefiting fully. Biosimilars are changing that. They offer comparable safety, purity, and efficacy at a lower price, and they are now one of the fastest-growing segments in pharmaceuticals.
Here is how the global market is performing, how it breaks down by region, and which companies are leading it.
Global Market Performance & Projections
According to Grand View Research, the global biosimilars market was valued at USD 39.6 billion in 2025. It is estimated at USD 46.4 billion in 2026 and is projected to reach USD 151.6 billion by 2033, a CAGR of 18.4% from 2026 to 2033.
Three forces drive this growth:
- Cost-effectiveness. Biosimilars are cheaper to develop than novel biologics because they need less R&D investment and shorter development timelines. Manufacturers can price competitively and still earn attractive margins.
- Chronic disease burden. Rising rates of cancer, autoimmune disorders, and diabetes are expanding the patient pool that needs long-term biologic therapy.
- Regulatory confidence. Approval pathways such as the U.S. FDA's require rigorous analytical, pharmacokinetic, and, where needed, clinical comparability. This has built physician and payer trust.
The savings are significant. Biosimilars delivered an estimated USD 12.4 billion in healthcare savings in 2023 alone, and about USD 36 billion since 2015. Oncology biosimilars have reached average discounts of roughly 52% for trastuzumab, 49% for bevacizumab, and 66% for rituximab. Projections suggest more than USD 130 billion in savings over the next decade.
Go Deeper! Ask Prism AI about the Global Biosimilars Market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.
Segment snapshot (2025):
- Drug class: Monoclonal antibodies led with a 44.9% revenue share. Insulin and analogues is the fastest-growing class, at a projected 20.53% CAGR.
- Indication: Autoimmune disorders led with a 39.9% share. Oncology is the fastest-growing indication, at a projected 19.53% CAGR.
- End use: Hospitals led with a 52.3% share, while specialty pharmacies are expanding at about 18.11% CAGR as home-based care grows.
Regional Breakdown
North America (42.6% revenue share in 2025). North America is the largest regional market. The U.S. leads, helped by strong healthcare infrastructure, a concentration of major pharmaceutical companies, and fast uptake of monoclonal antibody and insulin biosimilars. The 2025 wave of ustekinumab biosimilars, including Amgen's Wezlana, reflects how quickly competition is forming around high-value immunology drugs. In February 2025, the FDA also approved Merilog, the first rapid-acting insulin biosimilar.
Europe. Europe was an early adopter, and physician awareness of biosimilars is high. Patent expiries on key biologics continue to open the door to multiple entrants. The UK, Germany, and France each show steady growth, with hospitals central to distribution and multi-supplier competition keeping prices in check.
Asia Pacific (fastest-growing region). Asia Pacific is projected to grow at a 19.84% CAGR through 2033. Rising diabetes, cancer, and autoimmune disease prevalence, growing local manufacturing capacity, and expanding hospital and pharmacy networks are fueling demand. China is scaling production and uptake quickly, while Japan shows steady growth in insulin and monoclonal antibody biosimilars. The clinical pipeline is heavily weighted toward Chinese sponsors, which points to continued regional momentum.
Latin America. Adoption is rising, led by Brazil and supported by new product entries. In September 2025, Argentina approved Agalzyme, the first agalsidase beta biosimilar for Fabry disease. This is a sign of growing regional commitment to affordable access to high-cost therapies.
Middle East & Africa. Growth is more gradual but steady, driven by chronic disease prevalence and hospital-based care. Saudi Arabia is a notable market, with increasing biosimilar use in hospitals for chronic disease management.
Want a market view built around your priorities?
Need more countries, additional segments, or deeper competitor detail? Customize this report to your requirements, with 20% free customization.
Leading Industry Competitors
The market is highly competitive. Lower development costs and healthy margins keep drawing new entrants alongside established global pharmaceutical companies. The key players profiled include:
- Amgen Inc.
- F. Hoffmann-La Roche Ltd.
- Sandoz International GmbH
- Dr. Reddy's Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Samsung Bioepis
- Biocon
- Viatris Inc.
- Celltrion Healthcare Co., Ltd.
- AbbVie Inc.
Recent moves show where competition is heating up:
- Amgen launched Wezlana in January 2025, the first U.S. ustekinumab biosimilar referencing Stelara. Several other ustekinumab biosimilars followed in February.
- Biocon Biologics secured FDA approval for Jobevne (bevacizumab) in April 2025, bringing its U.S. oncology biosimilar portfolio to seven products.
- Celltrion made two biosimilars referencing Prolia and Xgeva commercially available in the U.S. in July 2025. In October 2025, its adalimumab biosimilar, Yuflyma, gained FDA approval for two new pediatric indications.
- Dr. Reddy's Laboratories continues to build its biosimilars presence through a dedicated biologics division focused on oncology, autoimmune, hematology, and nephrology.
The pipeline points the same way. Phase 2 and Phase 3 programs from sponsors such as Sandoz, Biocon Biologics, Formycon, and Shanghai Henlius Biotech suggest more launches ahead, more price competition, and likely consolidation and partnerships along the way.
What This Means for Stakeholders
For manufacturers, the opportunity lies in complex monoclonal antibodies, insulin, and oncology, and in emerging markets where affordability matters most. For payers and providers, growing competition within each molecule class increases negotiating leverage and expands access. Hospitals account for over half of biosimilar revenue, so understanding their purchasing dynamics is essential for anyone selling into this market.
Hospital and facility data for biosimilar strategy
Since hospitals are the largest end-use channel, explore Grand View Research's U.S. Healthcare Facility Database to identify and profile hospitals and other healthcare facilities as you plan your go-to-market approach.